The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kondratyeva E.I.

Research Centre for Medical Genetics;
Research Clinical Institute of Childhood

Avdeev S.N.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Kutsev S.I.

N.P. Bochkov Research Centre for Medical Genetics

History of the use of CFTR modulators in the treatment of cystic fibrosis

Authors:

Kondratyeva E.I., Avdeev S.N., Kutsev S.I.

More about the authors

Journal: Journal of Respiratory Medicine. 2025;1(3): 40‑50

DOI: 10.17116/respmed2025103140

Read: 168 times

Download PDF (RU)
Contact the author
Table of contents

HISTORY OF THE USE OF CFTR MODULATORS IN THE TREATMENT OF CYSTIC FIBROSIS
HISTORY OF THE USE OF CFTR MODULATORS IN THE TREATMENT OF CYSTIC FIBROSIS

To cite this article:

Kondratyeva EI, Avdeev SN, Kutsev SI. History of the use of CFTR modulators in the treatment of cystic fibrosis. Journal of Respiratory Medicine. 2025;1(3):40‑50. (In Russ.)
https://doi.org/10.17116/respmed2025103140

Подписка 2026 Респираторная медицина (Journal of Respiratory Medicine)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Pharmacoepidemiological study of oxaliplatin safety (analysis of Russian spontaneous repo­rting data­base). Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):76-83
Pathomorphology of chro­nic poly­pous puru­lent rhinosinusitis in cystic fibrosis in children. Russian Rhinology. 2025;(2):101-110
Sino­nasal pathology in patients with primary ciliary dyskinesia. Russian Rhinology. 2025;(3):223-232
Abstract:

Cystic fibrosis (CF) is the most common of the orphan lung diseases, well studied, not only highly sensitive diagnostic methods have been developed, cystic fibrosis centers with a multidisciplinary team and dynamic observation have been created, basic multicomponent therapy has been developed and targeted therapy has been connected for more than 10 years. The aim of the review was to study the history of CFTR modulators and evaluate their efficacy and safety. Based on the analysis of 79 scientific publications on targeted therapy for CF, an analysis of each drug was performed and a comparison of the efficacy of the last two most effective CFTR modulators, life expectancy and Vanzacaftor/tezacaftor/deitivacaftor. The primary and secondary indicators of the efficacy of CFTR modulators, adverse reactions, new problems associated with long-term use of drugs are discussed.

Keywords:

cystic fibrosis
CFTR modulators
potentiators
correctors
adverse reactions

Authors:

Kondratyeva E.I.

Research Centre for Medical Genetics;
Research Clinical Institute of Childhood

Avdeev S.N.

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Kutsev S.I.

N.P. Bochkov Research Centre for Medical Genetics

Received:

28.07.2025

Accepted:

25.08.2025

Close metadata

References:

  1. Cystic fibrosis. 2nd ed., rev. and enl. Kashirskaya NYu, Kapranov NI, Kondrat’eva EI, eds. Moscow: ID MEDPRAKTIKA-M; 2021. (In Russ.).
  2. Cystic Fibrosis Foundation. 2022 Patient Registry Annual Data Report. Bethesda (MD): Cystic Fibrosis Foundation; 2023. Accessed August 12, 2025. https://www.cff.org/media/31216/download
  3. Adamoli A, Orenti A, Zolin A, van Rens J, Prasad V, Fox A, Krasnyk M, Mayor SL, Naehrlich L, Gkolia P, Nieto AE, Bakkeheim E, Daneau G, Krivec U, Zomer D, Storms V, Jun A. ECFSPR annual report 2021. Karup (Denmark): European Cystic Fibrosis Society; 2023. Accessed August 12, 2025. https://www.ecfs.eu/sites/default/files/Annual%20Report_2021_09Jun2023.pdf
  4. Registr patsientov s mukovistsidozom v Rossiiskoi Federatsii. 2023 god. Amelina EL, Kashirskaya NYu, Kondrat’eva EI, Krasovskiy SA, Starinova MA, Voronkova AYu, Ginter EK, eds. Moscow: ID «MEDPRAKTIKA-M»; 2025. (In Russ.). https://doi.org/10.61726/1981.2025.26.16.001
  5. McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: advances and challenges. Pediatr Pulmonol. 2022;57(Suppl 1):S5-S12.  https://doi.org/10.1002/ppul.25733
  6. Scotet V, L’Hostis C, Férec C. The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery. Genes (Basel). 2020;11(6):589.  https://doi.org/10.3390/genes11060589
  7. Shadrina VV, Voronkova AYu, Starinova MA, Simonova OI, Sergienko DF, Semikin SYu, Kashirskaya NYu, Kondratieva EI. The effect of age and genotype on lung function in children with cystic fibrosis. Pulmonologiya. 2021;31(2):159-166. (In Russ.). https://doi.org/10.18093/0869-0189-2021-31-2-159-166
  8. Kutsev SI, Izhevskaya VL, Kondratyeva EI. Targeted therapy for cystic fibrosis. Pulmonologiya. 2021;31(2):226-236. (In Russ.). https://doi.org/10.18093/0869-0189-2021-31-2-226-236
  9. Clinical guidelines «Cystic fibrosis (mukovistsidoz)». 2021–2023. Approved by the Ministry of Health of the Russian Federation September 24, 2021. Accessed August 12, 2025. (In Russ.). https://mukoviscidoz.org/doc/%D0%9A%D0%A0372.pdf
  10. Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Robertson S, Green Y, Cooke J, Rosenfeld M; KIWI Study Group. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016;4(2):107-115.  https://doi.org/10.1016/S2213-2600(15)00545-7
  11. McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, Ratjen F, Sermet-Gaudelus I, Plant B, Munck A, Jiang Y, Gilmartin G, Davies JC; VX08-770-105 (PERSIST) Study Group. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). Lancet Respir Med. 2014;2(11):902-910.  https://doi.org/10.1016/S2213-2600(14)70218-8
  12. Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Chilvers M, Higgins M, Tian S, Cooke J, Davies JC; KLIMB study group. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2–5 years (KLIMB). J Cyst Fibros. 2019;18(6):838-843.  https://doi.org/10.1016/j.jcf.2019.03.009
  13. Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC; ARRIVAL study group. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med. 2018;6(7):545-553. 
  14. Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, Milla CE, Starner TD, Weiner DJ, Lee PS, Ratjen F. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med. 2013;1(8):630-638.  https://doi.org/10.1016/S2213-2600(13)70182-6
  15. Taylor-Cousar J, Niknian M, Gilmartin G, Pilewski JM; VX11-770-901 investigators. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: safety and efficacy in an expanded access program in the United States. J Cyst Fibros. 2016;15(1):116-122.  https://doi.org/10.1016/j.jcf.2015.01.008
  16. Cystic Fibrosis Foundation. Kalydeco approved mutations. Updated February 2022. Accessed August 12, 2025. https://www.cff.org/sites/default/files/2022-02/Kalydeco-Approved-Mutations.pdf
  17. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365:1663-1672. https://doi.org/10.1056/NEJMoa1105185
  18. Quittner A, Suthoff E, Rendas-Baum R, Bayliss MS, Sermet-Gaudelus I, Castiglione B, Vera-Llonch M. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial. Health Qual Life Outcomes. 2015;13:93.  https://doi.org/10.1186/s12955-015-0293-6
  19. McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir Med. 2019;7(4):325-335.  https://doi.org/10.1016/S2213-2600(18)30460-0
  20. Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2017;5(7):557-567.  https://doi.org/10.1016/S2213-2600(17)30215-1
  21. Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017;5(2):107-118.  https://doi.org/10.1016/S2213-2600(16)30427-1
  22. Rayment JH, Asfour F, Rosenfeld M, Higgins M, Liu L, Mascia M, Paz-Diaz H, Tian S, Zahigian R, McColley SA. A phase 3, open-label study of lumacaftor/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR. Am J Respir Crit Care Med. 2022;206(10):1239-1247. https://doi.org/10.1164/rccm.202204-0734OC
  23. Popowicz N, Wood J, Tai A, Morey S, Mulrennan S. Immediate effects of lumacaftor/ivacaftor administration on lung function in patients with severe cystic fibrosis lung disease. J Cyst Fibros. 2017;16(3):392-394.  https://doi.org/10.1016/j.jcf.2017.02.009
  24. Dagenais RVE, Su VC, Quon BS. Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review. J Clin Med. 2021;10(1):23.  https://doi.org/10.3390/jcm10010023
  25. Heneghan M, Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2023;11:CD010966. https://doi.org/10.1002/14651858.CD010966.pub4
  26. Munck A, Kerem E, Ellemunter H, Campbell D, Wang LT, Ahluwalia N, Owen CA, Wainwright C. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations. J Cyst Fibros. 2020;19(6):962-968.  https://doi.org/10.1016/j.jcf.2020.04.015
  27. Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC. Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med. 2017;377(21):2024-2035. https://doi.org/10.1056/NEJMoa1709847
  28. Davies JC, Sermet-Gaudelus I, Naehrlich L, Harris RS, Campbell D, Ahluwalia N, Short C, Haseltine E, Panorchan P, Saunders C, Owen CA, Wainwright CE; VX16-661-115 Investigator Group. A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. J Cyst Fibros. 2021;20:68-77.  https://doi.org/10.1016/j.jcf.2020.07.023
  29. Cystic Fibrosis Foundation. List of CFTR gene mutations responsive to Symdeko. Updated February 2022. Accessed August 12, 2025. https://www.cff.org/sites/default/files/2022-02/Symdeko-Approved-Mutations.pdf
  30. Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G; VX15-661-113 Investigator Group. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis. J Cyst Fibros. 2019;18(6):708-713.  https://doi.org/10.1016/j.jcf.2019.06.009
  31. Daines CL, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Rowe SM, Selvadurai H, Taylor-Cousar JL, Withers NJ, Ahluwalia N, Moskowitz SM, Prieto-Centurion V, Tan YV, Tian S, Weinstock T, Xuan F, Zhang Y, Ramsey B, Griese M; VX17-445-105 Study Group. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study. Eur Respir J. 2023;62(6):2202029. https://doi.org/10.1183/13993003.02029-2022
  32. Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809-1819. https://doi.org/10.1056/NEJMoa1908639
  33. Zemanick ET, Ramsey B, Sands D, McKone EF, Fajac I, Taylor-Cousar JL, Mall MA, Konstan MW, Nair N, Zhu J, Arteaga-Solis E, Van Goor F, McGarry L, Prieto-Centurion V, Sosnay PR, Bozic C, Waltz D, Mayer-Hamblett N. Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment. J Cyst Fibros. 2025;24(2):246-254.  https://doi.org/10.1016/j.jcf.2024.12.006
  34. Cystic Fibrosis Foundation. List of CFTR gene mutations approved for Trikafta (elexacaftor/tezacaftor/ivacaftor) on December 20, 2024. Accessed August 12, 2025. https://www.cff.org/sites/default/files/2022-02/Trikafta-Approved-Mutations.pdf
  35. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940-1948. https://doi.org/10.1016/S0140-6736(19)32597-8
  36. Ferreira FC, Buarque CD, Lopes-Pacheco M. Organic synthesis and current understanding of the mechanisms of CFTR modulator drugs ivacaftor, tezacaftor, and elexacaftor. Molecules. 2024;29(4):821.  https://doi.org/10.3390/molecules29040821
  37. Fiedorczuk K, Chen J. Molecular structures reveal synergistic rescue of ΔF508 CFTR by Trikafta modulators. Science. 2022;378(6618):284-290.  https://doi.org/10.1126/science.ade2216
  38. Laselva O, Bartlett C, Gunawardena TNA, Ouyang H, Eckford PDW, Moraes TJ, Bear CE, Gonska T. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. Eur Respir J. 2021;57:2002774. https://doi.org/10.1183/13993003.02774-2020
  39. Shaughnessy CA, Zeitlin PL, Bratcher PE. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci Rep. 2021;11:19810. https://doi.org/10.1038/s41598-021-99184-1
  40. Lopez A, Daly C, Vega-Hernandez G, MacGregor G, Rubin JL. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. J Cyst Fibros. 2023;22(4):607-614.  https://doi.org/10.1016/j.jcf.2023.02.004
  41. Stanke F, Pallenberg ST, Tamm S, Hedtfeld S, Eichhorn EM, Minso R, Hansen G, Welte T, Sauer-Heilborn A, Ringshausen FC, Junge S, Tümmler B, Dittrich AM. Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy. Front Pharmacol. 2023;14:1114584. https://doi.org/10.3389/fphar.2023.1114584
  42. Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA; VX18-445-109 study group. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med. 2022;10(3):267-277.  https://doi.org/10.1016/S2213-2600(21)00454-9
  43. Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros. 2022;21(2):265-271.  https://doi.org/10.1016/j.jcf.2021.11.012
  44. Ancel J, Launois C, Perotin JM, Ravoninjatovo B, Mulette P, Hagenburg J, Malet J, Griffon M, Carré S, Lebargy F, Deslée G, Dury S. Health-related quality of life in adults with cystic fibrosis: familial, occupational, social, and mental health predictors. Healthcare (Basel). 2022;10(7):1351. https://doi.org/10.3390/healthcare10071351
  45. Titova ON, Sukhovskaya OA, Gembitskaya TE, Kulikov VD. Otsenka kachestva zhizni podrostkov i vzroslykh, bol’nykh mukovistsidozom (obzor literatury). Ftiziatriya, pulmonologiya. 2023;11(2):20-26. (In Russ.). https://doi.org/10.36422/23076348-2023-11-2-20-26
  46. Zemanick ET, Konstan MW, VanDevanter DR, Rowe SM, Clancy JP, Odem-Davis K, Skalland M, Mayer-Hamblett N. Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. J Cyst Fibros. 2021 Nov;20(6):965-971.  https://doi.org/10.1016/j.jcf.2021.01.011
  47. Stanojevic S, Hamblett N, Szczesniak R, Cromwell E, Keogh R. Median age of survival in the 80s! Is there sufficient evidence to believe it? J Cyst Fibros. 2023;22(4):592-594.  https://doi.org/10.1016/j.jcf.2023.06.004
  48. Kenzhebaeva YZh, Mukatova IYu, Amelina EL, Rapil’bekova GK, Ivanova-Razumova TV, Tuleutaev ET. Pregnancy and delivery in a patient with cystic fibrosis on a reproduced CFTR modulator: the first clinical case in the Republic of Kazakhstan. Pulmonologiya. 2025;35(4):561-567. (In Russ.). https://doi.org/10.18093/0869-0189-2025-35-4-561-567
  49. Nash EF, Middleton PG, Taylor-Cousar JL. Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators — an international survey. J Cyst Fibros. 2020 Jul;19(4):521-526.  https://doi.org/10.1016/j.jcf.2020.02.018
  50. Khan HS, Tran P. Use of CFTR modulators in pregnancy: new information for neonatal, paediatrics and midwifery teams. Arch Dis Child Fetal Neonatal Ed. 2025;110:118-121.  https://doi.org/10.1136/archdischild-2023-325812
  51. Cimino G, Sorrenti S, Murciano M, Galoppi P, Ascenzioni F, Botta B, Brunelli R; Sapienza University Working Group on Cystic Fibrosis in Pregnancy. Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy. Arch Gynecol Obstet. 2024;309(1):9-15.  https://doi.org/10.1007/s00404-023-06962-5
  52. Mouzaki M, Dupuis A, Avolio J, Griffin K, Ratjen F, Tullis E, Gonska T. Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass. Front Pharmacol. 2023 Jul 13;14:1157459. https://doi.org/10.3389/fphar.2023.1157459
  53. King SJ, Tierney AC, Edgeworth D, Keating D, Williams E, Kotsimbos T, Button BM, Wilson JW. Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551D cystic fibrosis transmembrane conductance regulator mutation: a double-blind, placebo-controlled, randomized, crossover study with open-label extension. Nutrition. 2021 May;85:111124. https://doi.org/10.1016/j.nut.2020.111124
  54. Bailey J, Rozga M, McDonald CM, Bowser EK, Farnham K, Mangus M, Padula L, Porco K, Alvarez JA. Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an Evidence Analysis Center systematic review. J Acad Nutr Diet. 2021 Jul;121(7):1364-1378.e2.  https://doi.org/10.1016/j.jand.2020.03.014
  55. Sadras I, Cohen-Cymberknoh M, Kerem E, Koplewitz BZ, Simanovsky N, Wilschanski M, Birimberg-Schwartz L, Breuer O. Acute pancreatitis in pancreatic-insufficient cystic fibrosis patients treated with CFTR modulators. J Cyst Fibros. 2023;22(4):777-779.  https://doi.org/10.1016/j.jcf.2023.02.013
  56. Gould MJ, Smith H, Rayment JH, Machida H, Gonska T, Galante GJ. CFTR modulators increase risk of acute pancreatitis in pancreatic-insufficient patients with cystic fibrosis. J Cyst Fibros. 2022;21(4):600-602.  https://doi.org/10.1016/j.jcf.2021.09.010
  57. Gelzo M, Iacotucci P, Caputo M, Cernera G, Comegna M, Carnovale V, Corso G, Castaldo G. Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis. J Cyst Fibros. 2021;20(1):e1-e6.  https://doi.org/10.1016/j.jcf.2020.06.015
  58. Wisniewski BL, Aylward SC, Jordan CO, Kopp BT, Paul GR. Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based elexacaftor/tezacaftor/ivacaftor initiation in a preadolescent with cystic fibrosis. J Cyst Fibros. 2022;21(3):e217-e220. https://doi.org/10.1016/j.jcf.2022.01.010
  59. Miller MJ, Foroozan R. Papilledema and hypervitaminosis A after elexacaftor/tezacaftor/ivacaftor for cystic fibrosis. Can J Ophthalmol. 2022 Feb;57(1):e6-e10.  https://doi.org/10.1016/j.jcjo.2021.04.018
  60. Li A, Vigers T, Pyle L, Zemanick E, Nadeau K, Sagel SD, Chan CL. Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor. J Cyst Fibros. 2019 Jan;18(1):144-149.  https://doi.org/10.1016/j.jcf.2018.07.010
  61. Thomassen JC, Mueller MI, Alejandre Alcazar MA, Rietschel E. Effect of lumacaftor/ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients. J Cyst Fibros. 2018 Mar;17(2):271-275.  https://doi.org/10.1016/j.jcf.2017.11.016
  62. Scully KJ, Marchetti P, Sawicki GS, Uluer A, Cernadas M, Cagnina RE, Kennedy JC, Putman MS. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros. 2022;21(2):258-263.  https://doi.org/10.1016/j.jcf.2021.09.001
  63. Chan CL, Granados A, Moheet A, Singh S, Vigers T, Arbeláez AM, Yi Y, Hu S, Norris AW, Ode KL. Glycemia and β-cell function before and after elexacaftor/tezacaftor/ivacaftor in youth and adults with cystic fibrosis. J Clin Transl Endocrinol. 2022;30:100311. https://doi.org/10.1016/j.jcte.2022.100311
  64. Sermet-Gaudelus I, Delion M, Durieu I, Jacquot J, Hubert D. Bone demineralization is improved by ivacaftor in patients with cystic fibrosis carrying the p.Gly551Asp mutation. J Cyst Fibros. 2016;15(6):e67-e69.  https://doi.org/10.1016/j.jcf.2016.09.003
  65. Cystic Fibrosis Foundation. FDA approves new, once-a-day CFTR modulator for people with CF. Cystic Fibrosis Foundation. 2024 Dec 20. Accessed Aug 12, 2025. https://www.cff.org/news/2024-12/fda-approves-new-cftr-modulator
  66. Cystic Fibrosis Foundation. List of CFTR gene mutations responsive to TRIKAFTA. Cystic Fibrosis Foundation. Updated Dec 20, 2024. Accessed Aug 12, 2025. https://www.cff.org/media/35296/download?inline
  67. Cystic Fibrosis Foundation. FDA Approves New, Once-a-Day CFTR Modulator for People With CF. Cystic Fibrosis Foundation website. Published December 20, 2024. Accessed August 12, 2025. https://www.cff.org/news/2024-12/fda-approves-new-cftr-modulator
  68. Vertex Pharmaceuticals Incorporated, Cystic Fibrosis Foundation Therapeutics Inc. Clinical Study Protocol: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF) (VX20-121-102, Version 2.0, 20 August 2021). ClinicalTrials.gov. Accessed August 12, 2025. https://cdn.clinicaltrials.gov/largedocs/80/NCT05033080/Prot_000.pdf
  69. Vertex Pharmaceuticals Incorporated. Clinical Study Protocol: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation (VX20-121-103, Version 3.0, 19 August 2021). ClinicalTrials.gov. Accessed August 12, 2025. https://cdn.clinicaltrials.gov/largedocs/49/NCT05076149/Prot_000.pdf
  70. Keating C, Yonker LM, Vermeulen F, Prais D, Linnemann RW, Trimble A, Kotsimbos T, Mermis J, Braun AT, O’Carroll M, Sutharsan S, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Floreth T, Michelson P, Sosnay PR, Nair N, Zahigian R, Martin H, Ahluwalia N, Lam A, Horsley A; VX20-121-102 Study Group; VX20-121-103 Study Group. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. Lancet Respir Med. 2025;13(3):256-271.  https://doi.org/10.1016/S2213-2600(24)00411-9
  71. Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G; VX21-121-105 Study Group. Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. Lancet Respir Med. 2025;13(3):244-255.  https://doi.org/10.1016/S2213-2600(24)00407-7
  72. Vertex Pharmaceuticals Incorporated. TRIAL 1: A randomized, double-blind, Phase 3 trial in patients heterozygous for the F508del mutation and a minimal function mutation. TRIAL 2: A randomized, double-blind, Phase 3 trial in patients homozygous for F508del, heterozygous for F508del and a gating or residual function mutation, or with at least 1 other triple combination responsive CFTR mutation and no F508del mutation. Alyftrek HCP website. Accessed August 12, 2025. https://www.alyftrekhcp.com/trials-1-2
  73. Keogh RH, Tanner K, Simmonds NJ, Bilton D. The changing demography of the cystic fibrosis population: forecasting future numbers of adults in the UK. Sci Rep. 2020;10:8730. https://doi.org/10.1038/s41598-020-67353-3
  74. Clayton LJ, Shepherd AI, Corbett J, Perissiou M, Connett G, Legg J, Allenby M, Daniels T, Urquhart DS, Mackintosh KA, McNarry MA, Saynor ZL. Cardiovascular function in people with cystic fibrosis on elexacaftor/tezacaftor/ivacaftor: a cross-sectional, observational, single-centre study. J Cyst Fibros. 2025;24(4):801-808.  https://doi.org/10.1016/j.jcf.2025.02.001
  75. Montiel AF, Alvarez Fernandez A, Traversi L, Polverino E. The ageing of cystic fibrosis patients with new modulators: current gaps and challenges. Expert Rev Respir Med. 2023;17(12):1091-1094. https://doi.org/10.1080/17476348.2024.2311109
  76. Hadjiliadis D, Khoruts A, Zauber AG, et al. Cystic fibrosis colorectal cancer screening consensus recommendations. Gastroenterology. 2018;154(3):736-745.e14.  https://doi.org/10.1053/j.gastro.2017.12.012
  77. Indra R, Cerna V. The relationship between cancer risk and cystic fibrosis: the role of CFTR in cell growth and cancer development. RSC Med Chem. Published online May 27, 2025. https://doi.org/10.1039/d5md00203f
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.